Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Queensland Health
Medtronic
Chinese Patent Office
US Army
Boehringer Ingelheim
Accenture
Chubb
McKesson

Generated: May 25, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,772,209

« Back to Dashboard

Which drugs does patent 7,772,209 protect, and when does it expire?

Patent 7,772,209 protects ALIMTA and is included in one NDA.

Protection for ALIMTA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has fourteen patent family members in eleven countries.
Summary for Patent: 7,772,209
Title:Antifolate combination therapies
Abstract:A method of administering an antifolate to a mammal in need thereof, comprising administering an effective amount of said antifolate in combination with a methylmalonic acid lowering agent.
Inventor(s): Niyikiza; Clet (Indianapolis, IN)
Assignee: Eli Lilly and Company (Indianapolis, IN)
Application Number:11/776,329
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,772,209
Patent Claim Types:
see list of patent claims
Use; Delivery;

Drugs Protected by US Patent 7,772,209

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Lilly ALIMTA pemetrexed disodium INJECTABLE;IV (INFUSION) 021462-002 Sep 7, 2007 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Lilly ALIMTA pemetrexed disodium INJECTABLE;IV (INFUSION) 021462-001 Feb 4, 2004 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,772,209

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,053,065 Vitamin B12 and pemetrexed disodium combination therapies ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 7,772,209

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 359823 ➤ Try a Free Trial
Australia 6968801 ➤ Try a Free Trial
Cyprus 1107649 ➤ Try a Free Trial
Germany 60127970 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
UBS
Boehringer Ingelheim
McKinsey
Moodys
Harvard Business School
Baxter
US Army
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.